S1P lyase: A novel therapeutic target for ischemia reperfusion injury of the heart

Padmavathi Bandhuvula, Norman Honbo, Guan Ying Wang, Zhu Qiu Jin, Henrik Fyrst, Meng Zhang, Alexander D Borowsky, Lisa Dillard, Joel S. Karliner, Julie D. Saba

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that promotes cardiomyocyte survival and contributes to ischemic preconditioning. S1P lyase (SPL) is a stress-activated enzyme responsible for irreversible S1P catabolism. We hypothesized that SPL contributes to oxidative stress by depleting S1P pools available for cardioprotective signaling. Accordingly, we evaluated SPL inhibition as a strategy for reducing cardiac ischemia-reperfusion (I/R) injury. We measured SPL expression and enzyme activity in murine hearts. Basal SPL activity was low in wild-type cardiac tissue but was activated in response to 50 min of ischemia (n = 5, P < 0.01). Hearts of heterozygous SPL knockout mice exhibited reduced SPL activity, elevated S1P levels, smaller infarct size, and increased functional recovery after I/R compared with littermate controls (n = 5, P < 0.01). The small molecule tetrahydroxybutylimidazole (THI) is a Federal Drug Administration-approved food additive that inhibits SPL. When given overnight at 25 mg/l in drinking water, THI raised S1P levels and reduced SPL activity (n = 5, P < 0.01). THI reduced infarct size and enhanced hemodynamic recovery in response to 50 min of ischemia and to 40 min of reperfusion in ex vivo hearts (n = 7, P <.01). These data correlated with an increase in MAP kinase-interacting serine/threonine kinase 1, eukaryotic translation initiation factor 4E, and ribosomal protein S6 phosphorylation levels after I/R, suggesting that SPL inhibition enhances protein translation. Pretreatment with an S1P1 and S1P3 receptor antagonist partially reversed the effects of THI. These results reveal, for the first time, that SPL is an ischemia-induced enzyme that can be targeted as a novel strategy for preventing cardiac I/R injury.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume300
Issue number5
DOIs
StatePublished - May 2011

Keywords

  • Sgpl1
  • Sphingolipid
  • Sphingosine-1-phosphate

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'S1P lyase: A novel therapeutic target for ischemia reperfusion injury of the heart'. Together they form a unique fingerprint.

  • Cite this

    Bandhuvula, P., Honbo, N., Wang, G. Y., Jin, Z. Q., Fyrst, H., Zhang, M., Borowsky, A. D., Dillard, L., Karliner, J. S., & Saba, J. D. (2011). S1P lyase: A novel therapeutic target for ischemia reperfusion injury of the heart. American Journal of Physiology - Heart and Circulatory Physiology, 300(5). https://doi.org/10.1152/ajpheart.00946.2010